Shuttle Pharmaceuticals(SHPH.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Shuttle Pharmaceuticals
SHPH.US
Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. The company is developing Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas; and SP-2-225, a pre-clinical class IIb product candidate that effects on the regulation of the immune system. It is also developing SP-1-303, a pre-clinical selective Class I HDAC for use in the treatment of ER positive breast cancers; and SP-1-161, a HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway. The company was founded in 2012 and is headquartered in Gaithersburg, Maryland.
1.927 T
SHPH.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    What Does the Market Think About Shuttle Pharmaceuticals Holdings Inc?

    Shuttle Pharmaceuticals Holdings Inc (NYSE:SHPH) has seen a 42.49% decrease in short interest, with 160,000 shares sold short, representing 10.19% of available trading shares. It would take an average of 2.53 days for traders to cover their short positions. This decline in short interest may indicate a more bullish market sentiment. Compared to its peers, Shuttle's short interest is higher than the average of 10.14%.

    benzinga_article·
    US
    SHPH
    -4.90%
    benzinga_article·
    US
    SHPH
    -4.90%

    12 Health Care Stocks Moving In Tuesday's Intraday Session

    In Tuesday's intraday session, several health care stocks experienced significant movements. INVO Fertility (IVF) surged by 280.3% to $3.09, while Corvus Pharma (CRVS) rose by 97.76% to $15.92. Other gainers included Shuttle Pharmaceuticals (SHPH) up 69.93%, RAPT Therapeutics (RAPT) up 63.86%, and Aclaris Therapeutics (ACRS) up 41.79%. Conversely, NovaBay Pharmaceuticals (NBY) fell by 53.5% to $6.87, followed by Venus Concept (VERO) down 41.57%, and Jaguar Health (JAGX) down 38.47%.

    benzinga_article·
    US
    SHPH
    -4.90%
    benzinga_article·
    US
    SHPH
    -4.90%

    U.S. stock market midday update: Shuttle Pharmaceuticals up 153%! Clear capital flow, market sentiment triggers volatility attention

    Shuttle Pharmaceuticals rose 153.01%; RAPT Therapeutics rose 63.96%, with a transaction volume of USD 725 million; ImmunityBio rose 19.84%, with a transaction volume of USD 247 million; Corvus Pharmaceuticals rose 78.14%, with a transaction volume of USD 223 million; AbbVie fell 1.75%, with a market capitalization of USD 372.7 billion

    Tracking Unusual Activity·
    US
    SHPH
    -4.90%
    Tracking Unusual Activity·
    US
    SHPH
    -4.90%

    Pre-market hot trades in US stocks: Critical Metals up 10.08% pre-market; Shuttle Pharmaceuticals up 8.59% pre-market

    Critical Metals pre-market up 10.08%; Shuttle Pharmaceuticals pre-market up 8.59%; INVO Fertility pre-market up 464.99%; Icon Energy pre-market up 138.66%; RAPT Therapeutics pre-market up 63.42%

    Tracking Unusual Activity·
    US
    CRML
    +0.92%
    US
    SHPH
    -4.90%
    Tracking Unusual Activity·
    US
    CRML
    +0.92%
    US
    SHPH
    -4.90%

    Utah Approves AI Prescriptions Drugs. How AI Is Saving Time, Cutting Costs - and Why Molecule.ai's Drug Discovery Platform Matters More Than Ever

    Utah has become the first U.S. state to allow AI systems to authorize prescription refills without direct physician involvement, aiming to reduce healthcare costs and improve access. Shuttle Pharmaceuticals' Molecule.ai platform applies AI to streamline drug discovery, minimizing inefficiencies and costs associated with drug development. The initiative reflects a broader trend in healthcare towards automating routine decisions, while ensuring accountability and safety through expert oversight. The pilot program's results may influence future AI regulations in healthcare, promoting AI as a transformative tool in drug development.

    Newsfile Corp.·
    US
    SHPH
    -4.90%
    Newsfile Corp.·
    US
    SHPH
    -4.90%
    © 2026 Longbridge｜Disclaimer